693.63MMarket Cap-3598P/E (TTM)
0.960High0.920Low159.50KVolume0.940Open0.930Pre Close150.54KTurnover0.02%Turnover RatioLossP/E (Static)730.14MShares3.50052wk High0.20P/B693.63MFloat Cap0.85052wk Low--Dividend TTM730.14MShs Float52.600Historical High--Dividend LFY4.30%Amplitude0.850Historical Low0.943Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
BRII-B Stock Forum
There was HKD3.1 billion, HKD1.9 billion and HKD1.2 billion Southbound Trading net outflow from $TRACKER FUND OF HONG KONG (02800.HK)$, $Hang Seng H-Share Index ETF (02828.HK)$ and $TENCENT (00700.HK)$.
For $SH->HK Connect (GangGuTong)$, $MEITUAN-W (03690.HK)$ was the most active stock with highest net inflow of HKD527.1 million,...
YF Capital III is held by Jack Ma and $YUNFENG FIN (00376.HK)$ 's Chairman ...
I didn't buy it, but I hope it's approved in the US. If the US doesn't ratify it, but we do, frankly, it doesn't mean much. Second, in fact, the market is not too big, there are not many patients. So hopefully the FDA will approve it. That's the real litmus test
Among 837 patients at high risk of disease progression, the combined endpoint of hospitalization and death was 78% lower than that of placebo, according to a statement issued by Tengsheng Bo on August 25. That means the drug could reduce the death rate among hospitalized patients by 78%. The novel coronavirus neutralizing antibody drug is currently undergoing phase III clinical trials internationally. On September 8, a company official said that the international phase III clinical study of the company's novel coronavirus neutralizing antibody drug has achieved positive results, and the drug is only one step away from approval, which is expected to be approved by the end of this year.
No comment yet